NOMAD Bioscience receives patents in Japan and Australia for its antibacterials Salmocins

NOMAD Bioscience receives patents in Japan and Australia for its antibacterials Salmocins

Munich, October 2022 – NOMAD Bioscience GmbH has announced that the patent offices of Japan and Australia has issued the decisions to grant patents for NOMAD’s patent applications ‘Bacteriocins for the control of Salmonella enterica, JP2019-551665 and AU2018239310. The patents cover NOMAD’s Salmocins, non-antibiotic antibacterial proteins and the company’s lead product candidates for food and feed safety and veterinary markets. The first patent of this family has already been granted in USA (US11161886B2).

Salmonella enterica, Gram-negative bacteria contaminating food products are a major cause of bacterial enteric infections worldwide and the leading cause of deaths due to foodborne bacterial infections. NOMAD product candidates described and claimed in the patent application are antibacterial proteins Salmocins produced in plants and applied at very low concentrations; the products are highly and broadly active against all major pathogenic Salmonella strains causing food poisoning defined by USDA/FSIS as requiring priority control.

‘We are very pleased that the patent offices of Japan and Australia have allowed all essential claims in our submitted applications’, said Prof. Dr. Yuri Gleba, NOMAD’s CEO. ‘Our Salmocin product candidates have already received GRAS regulatory clearance in USA from FDA (GRN 824) and USDA (FSIS Directive 7120.1). These regulatory approvals, together with the broad patent protection, significantly strengthen NOMAD’s position as the leading provider of novel safety solutions for food and feed market.’

In addition to Salmocins, other plant-produced Bacteriocins of bacterial and bacteriophage origins are being developed by NOMAD as inexpensive food additives and food processing aids for the broad control of most common bacterial pathogens (Escherichia coli, Salmonella enterica and Clostridium perfringens) in food products. NOMAD is also actively developing Bacteriocins as medical alternatives to antibiotics, with its pre-clinical research focused on novel antibacterial proteins for control of major multi-drug resistant Gram-negative pathogens including Escherichia, Pseudomonas and Klebsiella. NOMAD is aggressively filing for patent protection of all its inventions related to Bacteriocins as food additives and medicines.

About NOMAD Bioscience GmbH. Nomad Bioscience GmbH is a plant biotechnology company developing a broad range of biotechnology products manufactured in plants. Corporate offices are headquartered in Munich, Germany and the Company’s Research Division is located in Halle, Germany. NOMAD Bioscience GmbH one subsidiary companies: UAB Nomads (Vilnius, Lithuania) and one spin-off Nambawan Biotech GmbH (Halle, Germany).

Contact info: gleba@nomadbioscience.com

Related articles

NOMADS UAB, Lithuania Published a Milestone Research Paper Describing its Chimeric Bacteriocins for Control of Multidrug-Resistant Pseudomonas

NOMADS UAB, Lithuania Published a Milestone Research Paper Describing its Chimeric Bacteriocins for Control of Multidrug-Resistant Pseudomonas NOMADS UAB, Lithuania,…

NOMAD Bioscience Broadens Its Agreements with Research and Commercial Growers, Spain, to Conduct Pilot Field and Greenhouse Trials Aimed at Industrial Manufacturing of Its Protein Products

NOMAD BIOSCIENCE Broadens Its Agreements with Research and Commercial Growers, Spain, to Conduct Pilot Field and Greenhouse Trials Aimed at…

NOMAD Bioscience Receives GRAS Regulatory Recognition by FEMA for Its Plant-Made Natural Thaumatin II as a Flavour Modifier/Enhancer

NOMAD Bioscience Receives GRAS Regulatory Recognition by FEMA for Its Plant-Made Natural Thaumatin II as a Flavour Modifier/Enhancer NOMAD Bioscience…

Prof. Dr. Yuri (Jurijus) Gleba, CEO and majority shareholder of NOMAD Bioscience, has supported Ukrainian Army by donating 100 thousand Euro to reinforce the defense against Russian aggression

Prof. Dr. Yuri (Jurijus) Gleba, CEO and majority shareholder of NOMAD Bioscience, has supported Ukrainian Army by donating 100 thousand…
Menü